Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study of experimental medication BMS-986235 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single ascending dose (SAD): BMS-986235 or Placebo | Experimental | BMS-986235 or Placebo oral dose |
|
| Multiple ascending dose (MAD): BMS-986235 or Placebo | Experimental | BMS-986235 or Placebo oral dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986235 | Drug | Specified dose on specified days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of serious adverse events (SAE) | Approximately 30 days | |
| Number of deaths | Approximately 30 days | |
| Number of adverse events (AE) leading to study discontinuation | Approximately 30 days | |
| Number of patients with clinically significant changes in ECG parameters, as defined by the investigator | Approximately 30 days | |
| Number of patients with potentially clinically significant changes in vital signs | Approximately 30 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim Clinical Trials | Anaheim | California | 92801 | United States | ||
| PRA Health Sciences |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38879891 | Derived | Singh J, Jackson KL, Fang H, Gumanti A, Claridge B, Tang FS, Kiriazis H, Salimova E, Parker AM, Nowell C, Woodman OL, Greening DW, Ritchie RH, Head GA, Qin CX. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovasc Res. 2024 Sep 21;120(11):1336-1350. doi: 10.1093/cvr/cvae103. |
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Specified dose on specified days |
|
| Salt Lake City |
| Utah |
| 84107 |
| United States |
| BMS Clinical Trial Patient Recruiting | View source |
| Investigator Inquiry Form | View source |
| FDA Safety Alerts and Recalls | View source |